Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts

Emergent BioSolutions Inc.

Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.
Elected directors DeGolyer, Fowler, White; say-on-pay passed; EY ratified as auditor.
Launched OTC NARCAN Nasal Spray; FDA approved two-dose anthrax vaccine CYFENDUS.
Won $379.6M DoD contract for RSDL kits and $235.8M contract for BioThrax.
Cut ~$240M annualized OpEx; extended secured credit facility to May 2025; divested Travel Health up to $380M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.